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THE DYNAMICS OF THE HYDROXYMETHYLOME AND METHYLOME 
DURING THE PROGRESSION OF ALZHEIMER’S DISEASE 
 
MICHAEL A. SMITH 
 
ABSTRACT 
Alzheimer’s disease (AD) is a neurodegenerative condition affecting millions of 
individuals worldwide and is a major source of mortality in elderly populations. While it 
is well established that there is a strong genetic basis for the disease, the epigenetic 
mechanism underlying the disease is largely unknown. The main purpose of this thesis is 
to understand the alteration of epigenetic modifications associated with the disease and its 
progression. In particular, we examine how alterations in the cytosine methylation and 
cytosine hydroxymethylation, two epigenetic modifications that are critically important 
for the development and function of the brain, are associated with advancing stages of 
Alzheimer’s disease. Eight progressive AD brain samples were examined for changes in 
DNA methylation and hydroxymethylation by both dot blot analysis and a new oxidative 
bisulfite (OXBS) deep sequencing technology. The initial results of dot blot analysis 
reveal a statistically significant decrease in 5hmC associated with intermediate stage AD 
among the samples.  This data suggests that the alterations in epigenetic modifications is 
likely associated with the pathophysiology of Alzheimer’s disease, not only shedding 
new light on our understanding of the epigenetics of the disease, but also providing the 
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basis for our  future investigation on the exact cause and effect relationships of these 
epigenetic changes and their respective stages in Alzheimer’s. 
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INTRODUCTION 
 
INTRODUCTION TO EPIGENETIC REGULATION 
Epigenetics refers to any type of inherited or acquired alteration to gene expression that is 
not due to changes in the ATCG coding sequence of the nucleic acid. Rather than focus 
on the largely immutable base-pair sequence-specific effects on genetic phenotype, the 
study of epigenetics describes how dynamic modifications to a genome affects the 
activity of genomic information.  Chemical modifications to DNA and chromatin by 
extrachromosomal enzymes, often in response to extracellular signaling, can augment or 
silence gene expression. (Rosenfeld 2010) These changes can be innate or acquired, and 
inheritable or non-inheritable. It is by these mechanisms that a wide diversity of 
differentiated cells found in multicellular organisms can arise from a single totipotent 
stem cell despite negligible alterations to the genetic code during the development 
process. (Arney and Fisher 2004) These processes are also involved in cellular 
homeostasis. The role of these processes in human disease, particularly in cancer, 
metabolic disorders, and neurological disorders hold a great deal of promise for next-
generation treatments. (Martin, Cropley, and Suter 2011) 
The need for dynamic and controlled expression of genomic information is paramount in 
multicellular organisms with many unique and specialized tissues. For instance, despite 
having the same genetic code as a cardiomyocyte, a heptocyte must produce several 
enzymes required for functions specific to the liver such as gluconeogenesis or 
ketogenesis all while specifically avoiding any production of cardiomyocyte-specific 
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proteins involved with contraction. At the same time, a cardiomyocyte, although it still 
possesses the genetic information to do so, does not produce enzymes such as ethanol 
dehydrogenase, cytochrome 450, or pyruvate decarboxylase which are produced at high 
levels in the liver. A cardiomyocyte will not produce any form of glucagon or insulin 
such as a cell in the pancreas nor will it adopt the unique shape of a neuron. 
The specialized epigenetic modification of the genome is a vital part of embryological 
development as the single totipotent zygote produced by fertilization gives rise to the 
fully differentiated cells and specialized tissues of an organism. Undifferentiated 
embryonic stem cells demonstrate high global levels of genome transcription. (Arney and 
Fisher 2004) However, as the embryo develops and the embryonic cells progress towards 
differentiation, several cellular mechanisms reprogram the genome. These mechanisms 
are promoted by extracellular cytokines, hormones, and growth factors. (Loebel et al. 
2003) There are two primary mechanisms by which the genome can be modified in order 
to alter gene expression– usually in response to messaging from these signaling 
molecules. Those two mechanisms are histone modification and DNA methylation. 
HISTONE MODIFICATION 
DNA in mammalian cells is tightly packaged in the nucleus using highly evolutionarily 
conserved histone proteins. This complex of histone protein and DNA is called 
chromatin. The basic unit of chromatin, which is compromised of an octomer of smaller 
globular proteins H2A, H2B, H3, and H4, is called a nucleosome. In the nucleosome, the 
histones are arranged in a fashion that leaves the N terminus, or histone tail, of the 
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histones unfolded and exposed. These histone tails are subject to heavy short term 
regulation by cellular enzymes that are capable of methylating, acetylating, 
phosphorylating, sumoylating, ubiquitinating and glycosylating specific amino acids on 
those tails. The modifications on those tails chemically control the spacing between each 
histone octomer and thereby control the overall structure of chromatin. Two general 
states of chromatin can be found across a packaged genome. Certain regions of chromatin 
are tightly and densely packaged and allow little transcription because they are not easily 
accessed by transcription factors. Such “closed” regions are called heterochromatin. In 
contrast, euchromatin is “open” and allows for high levels of transcription due to a loose 
packaging of histone proteins. Epigenetic control via histone modifications is a generally 
short-term mechanism. (Kraushaar and Zhao 2013) 
DNA METHYLATION 
DNA methylation is a highly established form of long-term epigenetic regulation that can 
be passed down between a parent and daughter cell. DNA methylation at the 5’ position 
of cytosine (5mC) is mediated the DNA methyltransferases (DNMTs) family of enzymes, 
which transfer a methyl group from S-adenosyl-L-homocysteine to their DNA substrate. 
There are five important DNMTs required for the establishment and maintenance of 
methylation across the genome. They are DNMT1, DNMT2, DNMT3a, DNMT3b, and 
DNMT3L, although DNMT2 specifically modifies RNA and DNMT3L does not have 
any catalytic activity. Due to the abundance of 5mC, it is considered the “fifth base” of 
DNA. The methylation process often occurs at the promoter regions of DNA containing 
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repeating clusters of cytosine and guanine dinuclotides called CpG islands. Such 
dinucleotides are important sites of promoter expression. Hypermethylated CpG regions 
show reduced expression while hypomethylated regions show increased expression. 
Presence of a methyl group at a CpG island recruits a methyl CpG Binding protein 
(MeCP1/2) that blocks the binding of transcriptional enzymes thereby silencing 
expression at this site. In addition, MeCP2 helps to recruit histone deactylase proteins to 
the region to promote the formation of heterochromatin. (Nan et al. 1998) Although there 
will be little emphasis on histone modification in this study, the connection between 
methylation regulation and histone modification regulation should be stressed. 
There are two primary types of methylation: de novo methylation and maintenance 
methylation. De novo methylation is the process by which undifferentiated cells have 
their genome specifically methylated in order to designate the cell down a particular route 
during the process differentiation. (Laurent et al. 2010) This reprogramming process is 
achieved by DNMT 3a/b. 
Maintenance methylation is a dynamic process by which the differentiated cell types both 
are able to maintain specific methylation patterns as the cells divide and replicate and 
also to respond to environmental signals. This process is catalyzed by DNMT1. As a cell 
divides and the genome replicates, the methylated parent strand serves as a template for 
the formation of an unmethylated daughter strand. This methylated parent and 
unmethylated daughter strand are called hemimethylated. The DNMT1 then uses the 
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hemimethylation as a template for full methylation of the daughter strand. (Chen et al. 
2014) 
DNA HYDROXYMETHYLATION 
Though it is a long-term modification, DNA methylation is not permanent nor is it 
immutable. The cell is able to effectively de-methylate the genome as needed. The 5 
hydroxylmethyl cytosine (5hmC) serves as an intermediate for demethylation of the CpG 
island.(H. Wu and Zhang 2011) This conversion of 5mC into 5hmC is accomplished via 
the action of the ten-eleven translocase (TET) family of enzymes. These enzymes use an 
alpha ketogluterate and oxygen to oxidize the methyl group on 5mC to make 5-
hydroxymethylcytosine (5hmC). Hydroxymethylcytosine can be further formylated and 
carboxylated to make 5- formylcytosine (5fC) and 5-carboxycytosine (5caC) 
respectively. These modifications can serve as an intermediate for the restoration of 
cytosine and the ultimate reactivation of the promoter region although the exact 
mechanism by which this orders is still contentious.  (L. Tan and Shi 2012) One possible 
mechanism of demethylation is called passive demethylation. This may occur as the 
genome replicates. DNMT1 may be unable to recognize 5hmC the same way it would 
recognize 5mC. Therefore methylation of hemimethylated DNA does not occur and 
daughter strands of DNA fail to become methylated like the parent strand. More direct 
mechanisms have been proposed. Although their existence is currently unconfirmed, 
decarboxylases and deformylases would be capable of recognizing 5caC and 5fC 
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respectively and removing those modifcations to restore unmethylated cytosine. Dynamic 
regulation of methylation and hydroxymethylation is very important for embryonic 
development and for maintenance of cellular homoeostasis. 
There are three Tet isoforms: TET1, TET2, and TET3. TET proteins are very important 
regulators of embryological neural development as well as the establishment of 
pluripotency in early embryological development.(Mayanil 2013)(Costa et al. 2013) 
TET1 and TET2 are expressed highly in embryonic stem cells and their expression is 
regulated heavily by OCT4 and Nanog, two transcription factors necessary for 
Figure 1: Pathways of dynamic cytosine methylation and demethylation. DNMT plays a role in de novo and 
maintenance formation of 5mC. The TET family of proteins lead to the oxidation formation of 5hmC followed by 5fC 
and 5CaC which can, by unconfirmed mechanism, be converted back into cytosine. Deamination followed by base 
excision repair can restore cytosine from 5mC and 5hmC. DNA replication is a passive process by which cytosine is 
restored by the loss of methylation and hydroxymethylation as the DNA strand is replicated. 
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maintaining pluripotency.(Costa et al. 2013)(Y. Wu et al. 2013) Consistently, control of 
methylation of CpG islands is an important factor in neural development. (Mayanil 2013) 
TET3 in particular is very important for neural development. (Xu et al. 2012) 5hmC is 
found in higher levels in the brain than in any other tissue in the body. This high level of 
hydroxymethylation corresponds with very high levels of gene activity. However, 5hmC 
in the brain seems to act as a stable epigenetic mark rather than as an intermediate for the 
eventual demethylation of 5mC. (Hahn et al. 2013) Altogether, these findings suggest 
that the dynamic regulation of DNA methylation and hydroxymethylation plays a key 
role the formation and maintenance of the brain. Already, there is a clear link between 
epigenetic dysfunction and several neurological diseases including Rett’s Syndrome, 
fragile X syndrome, Prader-Willi syndrome, Angelman syndrome, and Kabuki syndrome 
as well as with more ubiquitous diseases such as autism spectrum disorder, depression, 
schizophrenia, and chemical addiction. (Rangasamy, D’Mello, and Narayanan 2013) 
In addition to having roles in cellular differentiation, epigenetic mechanisms are highly 
involved in cellular metabolism and mammalian physiology. The dysregulation of several 
epigenetic processes are responsible for many forms of human disease. 
OXIDATIVE BISULFITE DEEP SEQUENCING 
This study will utilize a new sequencing technique called oxidative-bisulfite deep 
sequencing in order to distinguish the hydroxymethylome and methylome of any 
particular tissue sample. This technique stems from previous methods of determining 
genomic sequences. In order to properly establish the true methylome and 
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hydroxymethylome, it is necessary to first establish a next generation sequencing library 
for that particular genome. 
A next generation sequencing library is a full-genome sequence contained in a collection 
of fragments of genome that have all been ligated to a specific adaptor sequences. These 
fragments can then be sequenced using Illumina dye sequencing. Illumina dye 
sequencing operates by a form of shotgun sequencing. The genome must first be 
fragmented. There are several logistical reasons for this fragmentation. One is to break up 
the condensed genome into smaller linear fragments so that they can physically be read. 
The other and more important reason is so that many fragments can be sequenced 
simultaneously. This allows for much faster sequencing of the whole genome. Once the 
strand is fragmented, any 3’ overhangs are repaired. Based on the specific size 
restrictions of Illumina sequencing, only fragments of approximately 350 bp are selected. 
Then, the fragments are ligated to specific methylated adaptor sequences. 
The adaptors are unique to the technique of Illumina sequencing. They are 
complementary to the annealed sequences at bottom of an Illumina flow cell- a 
transparent membrane. Fragments with the ligated adaptor sequences are able to bind to 
the bottom of these flow cells. The adaptors also serve as binding sites for PCR primers 
that will repeatedly replicate a fragment by several orders of magnitude until it takes up 
an approximately 1 micron section of the flow cell called a DNA cluster. (Fang et al. 
2011)  Each cluster has a specific (x,y) coordinate on the blot cell, is made up of several 
copies of the same unique sequence and can be recognized and analyzed by a computer. 
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The actual sequencing strategy of shotgun sequencing varies from Sanger sequencing, the 
older generation form of sequencing that was used to during the human genome project. 
Sanger sequencing adds a non-reversible color specific phosphorescent ddNTPs to the 3’ 
end of each genomic fragment and separates the fragments by size in order to establish 
the sequence. (Morozova and Marra 2008) Shotgun sequencing works as a PCR reaction 
that can add one reversible florescent ddNTP at a time. The color of an entire DNA 
cluster will change as each ddNTP is added. As each base is added, the computer will 
record the color of each cluster and store the sequence of each one, allowing for the quick 
sequencing of millions of fragments at once. Once the base identity has been determined, 
the PCR reaction adds another base until it reaches the end of the fragment. The sequence 
of the entire genome is then reassembled due to overlapping sequences of the fragment. 
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Bisulfite sequencing (BS-seq) is capable of distinguishing modified cytosine from 
modified cytosine and thus can shed light on some of the epigenetic modifications on a 
strand of gDNA. Sodium bisulfite adds as a selective deaminating agent for cytosine. The 
addition of sodium bisulfite replaces the amine group on cytosine with a sulfite group to 
form a stable 6-sulfonyluracil intermediate. This sulfite group can then be removed 
completely in high pH. (Huang et al. 2010a) Upon deamination, cytosine becomes uracil. 
(Huang et al. 2010b) PCR amplification of that converted strand will replace that uracil 
Figure 2: Pathways of cytosine conversion during reaction with sodium bisulfite. 
Cytosine and hydroxymethylcytosine both react very quickly in the reaction while 
methylcytosine reacts slowly. The reaction product of hydroxymethylcytosine is still 
read as cytosine during Illumina dye sequencing. (Huang et al. 2010b) 
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with thymine and will be read as such. However, methylated and hydroxymethylated 
cytosine resists the deamination effects of the bisulfite and will still read as cytosine 
during sequencing. (Booth et al. 2013) Specifically, the methyl group of 5mC slows the 
deamination process by two full orders of magnitude while 5hmC reacts to form 
cytosine-5-methylenesulfonate which still is read as cytosine. (Huang et al. 2010a) This is 
why it is particularly important that the adaptors of the NGS library be methylated. If 
otherwise, the sequence of the adaptors would change upon exposure to the sodium 
bisulfite and they would not be able to anneal to the blot for later amplification and 
sequencing. 
 
Of course, to see where the modifications have taken place, this bisulfite-treated sequence 
must be compared to the sequence of an untreated gDNA strand. This is accomplished 
Figure 3: Strategy of Identifying all Variations of Cytosine. Since bisulfite conversion 
and sequencing can distinguish 5mC and 5hmC only from cytosine itself, the oxidation 
of 5hmC to 5fC is the best way to distinguish 5hmC from 5mC once the results of next 
generation, bisulfite, and oxidative bisulfite sequencing results are compared. (Booth 
et al. 2012) 
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with bioinformatic techniques that are capable of analyzing all the genomic information 
from the two strands at once. 
The major limitation of bisulfite sequencing is that it is incapable of distinguishing 
methylcytosine from hydroxymethylcytosine. However, one feature of 5hmC can be 
exploited to distinguish it from 5mC. 5hmC, when exposed to a selective oxidizing 
reagent potassium perruthenate (KRuO4), will convert to 5fC. 5fC, unlike 5hmC, is 
capable of becoming deaminated by the addition of sodium bisulfite and will appear as 
uracil and then as thymine when the treated strand is sequenced. Therefore, it becomes 
possible to ascertain the location of hydroxymethycytosines by comparing this sequence 
with that obtained by BS-seq and by next generation sequencing. Once is data is 
subtracted from the BS-seq data, all thymines not accounted for on NGS or BS 
sequencing correspond to 5hmC. Therefore, combination sequencing of BS-seq and 
oxBS-seq data will reveal the specific methylation and hydroxymethylation profiles of 
the genome. (Booth et al. 2013) Of course, the proper identification of the entire 
hydroxymethylome and methylome is dependent on comparing the sequences obtained 
by oxidative bisulfite sequencing and bisulfite sequencing to an unconverted next 
generation sequence. 
INTRODUCTION TO ALZHEIMER’S DISEASE 
The focus of this thesis will be to explore the epigenetic components that become 
deregulated and contribute to the progression of Alzheimer’s disease (AD). We intend to 
identify epigenetic components that can be manipulated for the eventual treatment of AD. 
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AD is a neurodegenerative disease affecting approximately 5.2 million Americans and 
approximately 50 million individuals worldwide. It is particularly prevalent among 
geriatrics, affecting 11% of the population above 65 years of age and 32% of the 
population above 85 years of age. (Ferri et al. 2005) (Mayeux and Yaakov 2012) 
Although much still has to be learned about the specific pathology and etiology of the 
disease, it is a well established hypothesis that neurodegeneration occurs as a result of 
increased neural apoptosis and necrosis relating to the accumulation of extracellular β-
amyloid fibrils and intracellular hyperphosophorylated tau protein into visible senile 
plaques.(Masters and Selkoe 2012) The degree to which these plaques have accumulated 
across different parts of the brain is measured as a particular value (I-VI) called the Braak 
scale. (Braak and Braak 1991) 
The precise mechanism by which the plaques lead to neurodegeneration remains 
controversial. Several pathways are associated with the progression of the disease. 
Defects in endocytosis and endocytosis may lead to increased extracellular deposition. 
Changes in lipid metabolism and clearance may be result in decreased clearance of the 
extracellular plaques. Changes in intracellular phosphatase and kinase activity promote 
the hyperphosphorylation of tau. The accumulation to plaques may lead to apoptosis via 
interference with proper neuronal calcium signaling (LaFerla 2002), mitochondrial 
oxidation and/or by capase activation via accumulation of AICD protein, a product of 
amyloid cleavage, in the endoplasmic reticulum (Kögel et al. 2012) (Takahashi et al. 
2009). There is also evidence to suggest that accumulations of amyloid fibrils can 
activate microglial cells via the Receptor for Advanced Glycation End Products (RAGE). 
 14 
 
Activation of this receptor leads to a NF-kb-mediated inflammation response which may 
contribute to neuron death. (Y. Wang et al. 2011) (Yan et al. 2012) Still other studies 
suggest that the accumulation of amyloid plaques are secondary effects of the disease and 
are not directly involved with the neurodegeneration. Instead, the same genetic defects 
and aberrant protein expression may lead to impaired protein and lipid transport that 
interfere with proper synaptic function. Such hypothesis are supported by studies in 
which patients present with amyloid plaques but without symptoms associated with 
Alzheimer’s disease. 
The exact etiology of the disease is likely due to an accumulation of several 
interconnected cellular pathways. Both amyloid and non-amyloid pathways have a 
genetic and epigenetic basis. 
Familiar early onset Alzheimer’s Disease (EOAD), which is characterized as AD onset at 
<60 years of age, can be traced to genetic polymorphisms of the amyloid precursor 
peptide (APP), Presenilin 1 (PSEN1), Presenilin 2(PSEN2) and Apolipoprotein E 
(APOE). The particularly pathogenic ε4 allele of the APOE is currently the strongest 
genetic risk factor for developing the disease. Individuals with a homozygous ε4 
genotype have a 90% chance of developing the disease.(Bertram and Tanzi 2012)(De-
Paula et al. 2012)(Tanzi 2012) These alleles are inherited in a Mendelian fashion. 
However, autosomal dominant mutations in the APP, PSEN1/2, and APOE gene regions 
accord only to cases of EOAD-a small fraction of total Alzheimer’s cases. (Lunnon and 
Mill 2013). Each are briefly discussed below. 
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Amyloid Precursor Protein 
Although the exact function of APP is unknown, it is theorized to participate in the 
formation of new synapses. (Priller et al. 2006) APP knockout (KO) mice show declined 
cognitive function and increased gliosis. (Dawson et al. 1999) APP is an integral 
membrane protein. Mutations in APP may be associated with altered transport of the 
protein to the membrane and/or altered cleavage of the protein.  Multiple lipid transport 
pathways regulate both the transport and the removal of APP from the cell membrane. 
Clathrin-coated pits have been shown to remove APP from the cell membrane via 
endocytosis. 
Although expression of APP increases with age, its expression has been shown to be 
lower in an advanced AD brain. (Barger et al. 2008) Strangely, the amount of APP 
expression in neurons decreases with increasing proximity to the neuron to a 
neurofibullary Aβ tangle in patients with advanced Alzheimer’s disease. (Matsuyama et 
al. 2007) 
Although expression of APP increases with age, its expression has been shown to be 
lower in an advanced AD brain. 
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Alpha Secretase 
The Alpha secretase family of proteases is described as a family of a disintegrin and 
metalloproteases (ADAMs). Overexpression of a particular ADAM (ADAM10) has been 
demonstrated to improve the formation of new synaptic junctions. (Bell et al. 2008) 
Alpha secretase makes the first cleave in APP during non-amyloid-producing pathway. 
 
Beta Secretase 
The sequential cleavage of Beta secretase by alpha and then gamma secretase produces 
the non-pathogenic P3 peptide. In contrast, sequential cleavage of APP by beta secretase 
followed by gamma secretase produces a protein that can be further cleaved by epsilon 
secretase to produce AICD and the pathogenic Aβ42 polypeptide. (Cole and Vassar 2007) 
Figure 4: Pathways of APP cleavage. This figure demonstrates the various cleavage pathways that amyloid precursor protein 
can go down. The specific products of cleavage depend on the identity and sequence of cleavage of the various proteolytic 
secretases interacting with APP. (Cole and Vassar 2007) 
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PSEN1/2 
Presenilin 1 and 2 (PSEN 1/2) are integral membrane proteins and components of the 
four protein presenilin complex. The presenilin complex is the catalytic domain of the 
gamma secretase. Mutations in PSEN1 are more associated with the development of AD 
than are mutations in PSEN2. (Suárez-Calvet et al. 2013) Mutations in the presenilins 
may be associated with altered cleavage of the APP protein or increased affinity for the 
APP β peptide- the product of beta secretase on the APP protein. 
 
APOE 
Apolipoprotien E is a lipid transporter unique to the brain. It is produced and secreted by 
astrocytes and microglial cells in the brain. Once secreted, it is the primary 
apolipoprotein of HDL in the brain. The brain is the most cholesterol-rich part of the 
body as it contains approximately 25% of the cholesterol in the body despite only 
comprising 2% of the total body mass. (Dietschy and Turley 2001) Much of that 
cholesterol is necessary in for the construction of complex lipids in the central nervous 
system such as the myelin sheath of neurons. Since cholesterol cannot pass the blood 
brain barrier, it must be produced in situ and removed via conversion to 24S-
hydroxycholesterol. (Hirsch-Reinshagen, L. Burgess, and Wellington 2013) For that 
reason, precisely controlled lipid transport is essential in the brain. 
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APOE also transports β-Amyloid plaques. There are two pathways by which amyloid is 
removed from the brain. Receptor-mediated endocytosis through microglial cells and 
astrocytes is one path. Transport through the blood brain barrier is the other. Defects or 
underexpression in APOE can lead to Alzheimer’s symptoms both due to decreased Aβ 
removal and due to impaired cholesterol transport. Interestingly, APOE expression is 
increased by progesterones. (Fan et al. 2013) However, APOE is shown to be expressed 
at higher levels in the AD brain. It remains to be seen if this is a compensatory action or 
if it is directly involved in the pathogenesis. (Martínez-Morillo et al. 2014) 
Other genetic contributions to the progression of the disease are being discovered. The 
genome wide association studies (GWAS) compiled genomic information from several 
Figure 5: Pathways of amyloid recycling via APOE. APOE functions in removing amyloid deposits my mobilizing it back to 
neurons and microglia for endocytosis-mediated degradation or by transport to the blood brain barrier. (Hirsch-
Reinshagen, L. Burgess, and Wellington 2013) 
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Alzheimer’s cases and identified several other genes that are associated with increased 
risk of the disease. Among them, mutations of the genes ABCA7, BIN1, CD2AP, CD33, 
CLU, CR1, EPHA1, MS4A, and PICALM and URPG have been shown to be associated 
with the disease. (Waring SC and Rosenberg RN 2008) 
 
CLU 
Clusterin, also known as Apolipoprotien J, is another apolipoprotein associated with lipid 
metabolism in the brain. It has two forms: a pro-apoptotic cytoplasmic form and secreted 
from the cell. Clusterin is expressed in high quantities in response to cerebral trauma or 
neuroinflammation. (Loison et al. 2006)  Its effects are similar to those of APOE. It has 
been shown to bind with amyloid, prevent the formation of amyloid fibrils and assist with 
its removal from the brain. In addition, it has an important role in regulating 
neuroinflamation, cell death, and lipid metabolism. (Desikan RS et al. 2013) 
 
PICALM 
Phosphatidylinositol-binding clathrin assembly protein (PICALM) is essential in the 
formation of clatherin-coated pits that are needed for the removal of APP from the lipid 
membrane of the neuron. (Ando et al. 2013) 
 
ABCA7 
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ATP-binding Cassette transporter 7 is a lipid transporter for immune cells. Expression of 
ABCA7 is increased by the presence of LDL and decreased by the presence of HDL High 
levels of expression are associated with decreased AD risk, but expression also increases 
as the disease progresses, indicating that increased expression is a compensatory measure 
BIN1 
Bridging integrator 1 (BIN1) is second only to APOE in its association with Alzheimer ’s 
disease. It is present in all tissue by is highly expressed in brain and muscle tissue. It has 
several know functions, several of which may be associated with AD pathology. It is 
involved with the amyloid exocytosis pathway, calcium signaling.(M.-S. Tan, Yu, and 
Tan 2013) It is a myc-associated binding protein involved with apoptosis and also has 
interactions with tau. It has been shown to be highly upregulated in AD brains. (Chapuis 
et al. 2013) 
EGR1 
Early Growth Response 1 (ERG1) is a zinc finger transcription factor that promotes the 
production of Cdk5. Active Cdk5 phosphorylates Tau protein. AD brain samples have 
shown that ERG1 is upregulated as compared to healthy controls. This increased 
phosphorylation leads to decreased stability of neuronal microtubules (Lu et al. 2011) It 
is upregulated in response to a number of physiological factors including immune 
response, growth factor stimulation, and brain trauma. (Beckmann and Wilce 1997) 
(McMahon and Monroe 1996) 
THE RELATIONSHIP BETWEEEN EPIGENETICS AND ALZHEIMERS 
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DISEASE 
Although there is a strong genetic basis for the pathology of Alzheimer’s Disease, 
inheritance of genetic polymorphisms account for less than 10% of AD cases.(Lunnon 
and Mill 2013) It is clear that classical genetics offers only partial explanations about the 
onset of disease. 
Twin studies of monozygotic twins have shown that the development of the disease and 
the age of onset can vary considerably, suggesting that other factors may play a large role 
in the progression of the disease. (Räihä et al. 1997) 
While Mendelian inheritance can explain some of the progression of the disease, 
epigenetic considerations may hold a promise of further understanding the disease and 
better treating it in the foreseeable future. Support for an epigenetic routes of disease 
progression emerged after it was observed that individuals with trisomy-21, also known 
as Down Syndrome, have drastically increased rates of Early Onset Alzheimer’s Disease. 
It has been hypothesized that the EOAD phenotype results from increased APP protein 
production due to the presence of the third copy of the APP gene, which is located on 
chromosome 21. (Wilcock and Griffin 2013) 
The primary risk factor for developing AD is age. Even with individuals who carry risky 
alleles for the disease, the probability of developing the disease at a young or middle age 
is staggeringly low. There are several physiological changes in the body associated with 
advancing age including decreased sex steroid signaling, increased inflammation, altered 
glucose metabolism that are tightly involved with regulation of the epigenome. 
Regulation of the DNA methylome has been shown to change with advanced age. 
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(Laurent et al. 2010) In the brain, age is positively correlated with decreases in 
methylation and increases in hydroxymethylation. (S.-C. Wang, Oelze, and Schumacher 
2008a) (Wilson et al. 1987) The presence of amyloid plaques in particular seems to 
exacerbate dysregulation of the methyome in the brain. (Taher et al. 2013) In addition, 
altered methylation patterns in aging brains have been linked to dysregulation of APP and 
tau. (Iwata et al. 2013) 
Newer developments have indicated several genes in addition to those with known 
disease-prone alleles that are differentially expressed in the case of Alzheimer’s disease 
compared to a healthy cohort. Several studies show that expression levels change both 
overtime during Alzheimer’s and temporally with different sections of the brain 
responding differently. (Winnie S. Liang et al. 2010) (W. S. Liang et al. 2008) Some of 
the involved genes are SORT1, ABCA1, MAPT, CDK5, and GSK-3B. 
SORT1 
Sortilin is a receptor on neurons that may play a role in the endocytosis of APOE and β-
amyloid complexes. In vivo studies have shown that down-regulation of SORT1 leads to 
exacerbated Aβ disposition. (Rogaeva et al. 2007) 
ABCA1 
ATP-binding Cassette Transporter A1 is an important lipid transporter responsible for 
lipating APOE and the CNS HDL lipid transporters. Defects in ABCA1 lead to an 80% 
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loss of functional APOE. Overexpression of ABCA1 in mice leads to decreased amyloid 
deposition. (Hirsch-Reinshagen, L. Burgess, and Wellington 2013) (Wahrle et al. 2008) 
MAPT 
Microtubule-associated protein tau is a protein needed to stabilize axonal microtubules 
necessary for transport of neurotransmitters from the cell body to the synaptic junction. In 
addition, these microtubules are necessary for the formation of new synaptic junctions. 
Unphosphorylated tau proteins are necessary for building up the microtubules. The 
mechanism by which the microtubules are recycled and broken down involves 
phosphorylation of tau. Excess phosphorylation of tau leads to the formation of insoluble 
intraneuronal deposits of phosphorylated tau called neurofibrillary tangles- the main 
pathological hallmark of AD progression. MAPT is shown to be upregulated in an AD 
brain. There are two possible explanations for the link between increased MAPT 
expression and the formation of the tangles. One is that an originally increased MAPT 
expression invariably leads to more tau protein, phosphorylated or otherwise. Another 
possibility is that an original increase in the activity of tau kinases leads to a decrease in 
unphosphorylated tau and the increase in MAPT activity represents an epigenetic 
compensatory response on the part of the neuron.  Tau is largely phosphorylated by 
CDK5 and GSK-3B.(Jayapalan and Natarajan 2013) 
CDK5 
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine–threonine kinase that 
phosphorylates tau on S202, T212, S396, and S404. Increased activity of Cdk5 is 
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associated with the progression of Alzheimer’s diseases.(Shukla, Skuntz, and Pant 2012) 
The process by which Cdk5 activity is increased is well established. 
GSK-3B 
Glycogen synthase kinase 3 beta tightly regulates the activity of several enzymes 
involved with glucose metabolism including glycogen synthase. It has also been shown to 
phosphorylate several other enzymes. Glycogen synthase kinase-3B is upregulated in an 
AD brain. The mechanism by which it is upregulated may be that the extracellular 
accumulation of amyloid blocks Wing Integrase (wnt) signaling and thereby prevents 
inhibition of GSK-3B.(Hernández et al. 2010) Once active, GSK-3B is a kinase for both 
tau and presenilin. (Hernández et al. 2010) (Takashima 2006) It has also been shown that 
its activity is pro-apoptotic. 
Though Alzheimer’s epigenetics is still in its infancy, several viable epigenetic 
mechanisms have been proposed. One major epigenetic process for which there is a 
strong association with Alzheimer’s disease is DNA methylation. DNA methylation of 
promoter regions is a key point of genetic regulation. 
The genomic methylation profiles of Alzheimer’s patients vary from those of healthy 
individuals of the same age group. (S.-C. Wang, Oelze, and Schumacher 2008b) 
(Johansson, Enroth, and Gyllensten 2013) (Rao et al. 2012) (Bradley-Whitman and 
Lovell 2013) Some degree of differential DNA methylation is associated with aging 
(Bakulski et al. 2012) According to a hypothesis involving DNA-methylation, genetic 
factors promoting the formation of β-amyloid deposits as well as those promoting tau 
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production and phosphorylated are being increasingly overexpressed in Alzheimer’s 
brain, either by hypomethylation or by excessive hydroxylmethylation, and/or genetic 
factors disrupting β-amyloid deposition and tau phosphorylation are down-regulated, 
likely because they are being inappropriately hypermethylated due to a loss of proper 
epigenetic homoeostatic controls including TET. For this report, we would like to 
examine the relationship between epigenetic modification of 5mC and 5hmC and the 
progression of the disease. 
This examination will be achieved using a new sequencing technique called oxidative 
bisulfite deep sequencing which is capable of showing the entire hydroxymethylome and 
methylome. This study will be performed using eight brain samples at distinct stages in 
the disease progression. 
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GOALS AND QUESTIONS 
A. Establish trends in methylation and hydroxymethylation in the genome as the 
disease progresses. 
How are global DNA modifications altered during disease progression? We wish to 
establish a firm link between the progression of the disease and changes in global DNA 
modification during that progression. Changes in global trends of hydroxymethylation 
and methylation, though it can tell us very little about the specific expression patterns of 
many of the genes associated with AD, can provide two useful pieces of information. If a 
significant trend can be established, this trend may be able help predict or track AD 
progression in a clinical setting. More importantly for a laboratory setting, global changes 
in these methylation and hydroxymethylation can help establish which DNA-modifying 
enzymes are most involved with the progression of the disease. 
This can fortunately be accomplished with simpler and cheaper techniques than 
sequencing. We will attempt to answer this question using a dot blot. Previous studies 
have shown that, compared to healthy individuals of the same age, hydroxymethylation 
and methylation levels are both lower in the AD brain. (Mastroeni et al. 2010) However, 
we hope to see at which points during the progression of the disease that these changes 
are most drastic. 
B. Establish an epigenetic signature of the AD brain 
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The epigenetic signature of the AD brain refers to the unique epigenetic modifications 
that are present in the genome an AD brain that can be contrasted with those on a healthy 
genome. This goes beyond the general trends in global methylation and 
hydroxymethylation as mentioned the first goal. Specifically, we hope to see which 
unique modifications in which sections of the genome are most associated with the 
progression of the disease and how these modifications can serve as a basis for predicting 
the onset and progression of the disease. 
C. Establish which genes are the most differentially expressed during the progression 
of the disease. 
Which genes associated with the progression of the disease are activated or suppressed at 
which stages in the disease? If we have the sequences of the methylome and 
hydroxymethylome at different stages in the progression of the disease for specific genes, 
the data could provide more insights into the pathophysiology of the disease. For 
instance, we could distinguish which genes are differently regulated as consequences or 
as compensatory reactions to the AD progression and which ones are originally altered to 
manifest in AD symptoms. 
D. Establish physiological mechanisms promoting the progression of the disease. 
Should this study find a clear relationship between changes in DNA methylation of 
promoter regions of key Alzheimer’s genes and the progression of the disease, there will 
be fertile new research areas for Alzheimer’s study and treatment. Specifically, this will 
help establish an outline for the specific role that DNMTs, TETs, and other epigenetic 
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enzymes have in the disease and what extracellular and intracellular signals and pathways 
help localize these enzymes to the target sequences. 
For instance, we have previously demonstrated that TET expression is altered by estrogen 
signaling in a breast cancer cell model. Increased estrogen signaling can increase the 
expression of TET2. However, this has not yet been demonstrated in a neuronal cell line 
though our group has evidence to suspect that some of this effect is preserved in neurons. 
The risk of developing AD increases significantly after menopause. There is evidence to 
suggest that estrogen hormone replacement therapy (HRT) and the angonistic effects of 
Selective Estrogen Receptor Modulators (SERMs) can decrease the risk of developing 
Alzheimer’s disease.(Henderson 2009) Tamoxifen, an important SERM used to treat 
breast cancer, acts as an estrogen antagonist that can downregulate estrogen receptor in 
breast tissue. However, it has agonistic effects in other tissues including in bone and 
brain. Deciphering how the TETs are involved during the dynamic alteration of the 
hydroxymethylome and methylome and how these alter gene expression during the 
progression of Alzheimer’s disease presents a potentially fruitful avenue to better 
understand and treat the disease. 
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MATERIALS AND METHODS 
Preparation of Brain Tissue 
Brain samples were obtained through the Alzheimer’s Disease Center at Boston 
University School of Medicine. A total of eight samples were obtained. Two were 
disease-free control samples. Two were early-stage brain samples (Braak I/II), two were 
intermediate stage (Braak III/IV), and two were late stage (Braak V/VI) samples all 
obtained from the pre-frontal cortex. The pre-frontal cortex was chosen due to its 
relatively large size compared to other parts of the brain associated with AD such as the 
hippocampus. Samples were delivered on dry ice and stored at -20 degrees C. Once ready 
for preparation, brain samples were wrapped in aluminum foil and immersed in liquid 
nitrogen for one minute. Then, using a mortar and pestle, the brain samples were ground 
into a course powder that could be massed with greater ease. The brain samples did not 
readily stay in a solid state, resulting in the samples quickly thawing within seconds into 
a gelatinous and cohesive stage. This made massing and storing the sample quite 
difficult. This was remedied by constantly re-submerging ground samples in liquid 
nitrogen and massing while on dry ice. Once the ground samples were obtained, 25 mg 
were massed and placed in a 1.7 ml centrifuge tube on dry ice. 
 
Genomic DNA Extraction 
The extraction of genomic DNA was performed using a Qiagen DNeasy Tissue Kit. The 
samples were mixed with 180 ul of proteinase K digestion buffer with 20 ul of proteinase 
K and placed in 56 degrees C water bath and left to digest over night in order to fully 
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disintegrate the tissue sample. Then, 200 ul of a lysis buffer was added to break up the 
cells. 200 ul of ethanol was added in order to make the DNA less soluble. The solution 
was then passed through a spin column and membrane. The membrane was washed to 
remove all cellular components not bound to the genome. Finally, the genome was 
obtained by washing the membrane twice with 100 ul of elution buffer. Once obtained, 
the genomic DNA was quantified using a Nanodrop apparatus and again with a Qubit 
apparatus. 
 
Ammonium Acetate and Isopropanol Precipitation of Genome 
Initial genomic DNA yields as determined by Qubit analysis were particularly low. For 
that reason, genome extraction was repeated ten times for each sample of brain and 
combined together to form 1 ml of total elute. Once these samples were combined, the 
total elute was concentrated by adding 100 ul of 3M sodium acetate followed by 1.0 ml 
of isopropanol to precipitate the DNA. Once a cloudy precipitate was observed in each 
sample, the solution was centrifuged at 14,000 rpm for 5 minutes to pellet the DNA. The 
supernatant was aspirated and the DNA pellet was washed twice with 750 ul of 70% 
ethanol. The pellet was resuspended in 100 ul of ultra pure water and analyzed again with 
a Qubit apparatus. 
 
Dot Blot Analysis 
In order to confirm the presence of genomic DNA, a dot blot was performed using an 
anti-5hmC primary antibody. A dot blot is a quantitative method for detecting levels of a 
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target antigen using a primary antibody specific for the antigen of choice. In this 
experiment, antibodies for 5mC, 5hmC, 5fC, and 5caC were used. This experiment was 
performed first by obtaining an aliquot of each genome sample and sonicating it for 10 
seconds to break up the genome into smaller segments. Two samples of genomic DNA 
from exactly 120 ng of each sonicated genome sample solution were obtained and placed 
in a 96 well PCR plate. The solution in each well was diluted to 60 ul using TE buffer. 
Four two-fold serial dilutions for each sample were made across the PCR plate. To each 
well, 20 ul of 1M NaOH/25mM EDTA was added. The plate was then placed in a PCR 
machine for 10 minutes at 95˚ C in order to separate the strands of the double helix. 50 ul 
of cold ammonium acetate was then added to each well. 
At the same time, a 0.2 um nitrocellulose membrane was cut and prepared. It was placed 
inside a Bio-Rad dot blot apparatus and hydrated with TE buffer. Genomic DNA from 
each well on the PCR plate was added to their respective wells on the dot blot apparatus 
and was bound to the membrane using vacuum filtration of the genomic solution. The 
membrane was washed with SSC solution to enhance genomic DNA binding. Once the 
DNA had been bound, the membrane was left in a 56˚ C incubator and left to dry for 20 
minutes. Immediately after, it was placed under UV light for 20 minutes to promote cross 
linking of the genomic DNA to the membrane. After, it was placed for one hour in a 5% 
non-fat milk and Phosphate buffered solution + Tween (PBS-T) in order to prevent non-
specific antibody interactions. The membrane was then left overnight in a 5% milk PBS-
T solution with a rabbit 5hmC antiserum. The next day, it was washed three times with 
PBS-T and then reacted with a goat anti-rabbit serum. After washing three times with 
 32 
 
PBS-T, the membrane was reacted with 5 ml of Western Lightning ECL luminol solution 
and 5 ml of Western Lightning ECL oxidizing solution. In a dark room, the membrane 
was used to expose medical x-ray film for 20 seconds. 
This procedure was repeated with primary rabbit antibodies specific to 5mC, 5fC, and 
5caC. Due to limitations in the amount of DNA that could be responsibly devoted to the 
dot blot analysis, this procedure was performed once for each primary antibody. 
 
Illumina Dye Preparation of Genomic DNA 
Fragmentation of DNA 
To generate a Next Generation Sequencing Library (NGS) obtained DNA was quantified 
using Qubit analysis. 50 ul of 20 ng/ul gDNA of each sample was obtained. The samples 
were placed in a 96 0.3 ml PCR plate and sonicated. 80 ul of magnetic sample 
purification beads were added to each well mixing evenly by pipetting several times. The 
samples were then left to incubate for five minutes. Then, using a magnetic stand, the 
samples were left sitting for eight minutes while the beads were pulled out of solution. 
Completion of this process was marked by the liquid becoming translucent. The 
supernatant was then removed with the PCR plate still on the magnet. 
Purification of fragmented DNA 
The beads were then washed twice by adding 200 ul of 80% ethanol, incubating the 
samples for 30 seconds and then removing the supernatant. The ethanol was allowed to 
evaporate. With the plate still on the magnetic plate, 52.5 ul of respension buffer was 
added to each sample. The plate was then removed from the magnetic plate. The solution 
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was pipetted repeatedly to resuspend the beads. At this point, the nucleic acid will elute 
from the beads. The plate was placed again on the magnetic plate. The supernatant from 
each sample was then removed and then placed in wells of a new 96 0.3 ml PCR plate. 
Repair of the 3’ Overhangs 
To each sample well in the PCR plate, 10 ul of Resuspension buffer followed by 40 ul of 
end repair mix 2 were added. The PCR plate was then placed in a thermocycler where it 
was preheated to 100˚ C and then run at 30˚ C for 30 minutes. This PCR reaction acts to 
seal any 3’ overhangs in the fragmented DNA so that all DNA fragments have blunt ends. 
Removal of Significantly Larger or Smaller than 350 bp 
Each sample was run on 
Adenylation of 3’ Ends 
In order to prevent fragments from ligating to each other and forming chimera fragments 
upon addition of the adaptors, each fragment was given a 3’ poly adenosine tail. To each 
sample, 2.5 ul of resuspension buffer followed by 12.5 ul of A-tailing mix was added. 
The PCR plate was then place in a thermocycler and preheated to 100˚ C. It was then run 
at 37˚ C for 30 minutes, 70˚ C for 5 minutes and finally at 4˚ C for 5 minutes. 
Ligation of Adapters 
To each sample, 2.5 ul of resuspension buffer followed by 2.5 ul of ligation mix 2 were 
added. Then 2.5 ul of DNA Adapter was added. The PCR plate was placed in a 
thermocycler and preheated to 100˚ C. The samples were incubated at 30˚ C for 10 
minutes and then cooled to 4˚ C. 5 ul of Stop Ligation Buffer was added to each well 
following incubation. The fragments were then washed using 42.5 ul of magnetic sample 
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purification beads. The beads were once again washed by placing the samples on a 
magnetic bar, removing the supernatant and adding 200 ul of 80% ethanol twice. Once 
the ethanol was removed the second time, the samples were resuspended in 52.5 ul of 
resuspension buffer. This final Next Generation Sequencing Library (NGS) was then sent 
to Illumina Dye Sequencing in Shanghai, China. 
 
Oxidative Bisulfite Preparation of Genomic DNA 
End Ligation of Genomic DNA 
Obtained genomic DNA was quantified using Qubit analysis. Obtained genomic DNA 
was treated with an end repair kit in order to seal any 3’ overhangs of the obtained 
genomic DNA. 
DNA Oxidation 
The sample of remaining NGS library was split in half with one half designated for DNA 
oxidation and one sample designated for mock DNA oxidation. 
Using the sample designated for DNA oxidation, a Bio-Rad P6 Micro-Bio spin column 
was prepared by flicking the column and centrifuging at 1000 x g in order to settle the 
spin column matrix. The top cap and bottom were removed and the column was placed in 
a 2.0 ml wash tube. Once placed in the tube, the column was centrifuged for 120 seconds 
at 1000 x g. The column was washed three times with 500 ul of Ultra Pure water and 
centrifuged at 1000 x g for 120 seconds a total of four times. 20 ul of gDNA of each 
sample was added its own respective column and centrifuged at 1000 x g for 120 
seconds. 
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The gDNA from both the DNA oxidation samples and the DNA mock oxidation samples 
was then denatured by adding 1.25 ul of denaturing solution and enough Ultra Pure water 
to bring the final solution to 24 ul for each sample. This solution was added to a 0.2 ml 
tube and placed in thermocycler and incubated at 37˚ C for 30 minutes. After being 
allowed to cool on ice, each sample from the DNA oxidation designation was reacted 
with 1 ul of oxidant solution and placed back in the thermocycler for 30 minutes at 40˚ C. 
The mock oxidation samples were treated with 1 ul of ultra pure water and placed on the 
same thermocycler program. These samples were then centrifuged at 14000 x g for 10 
minutes in order to remove any black precipitate. 
Bisulfite Conversion 
A bisulfite reagent solution was prepared by dissolving Bisulfite Reagent in 700 ul of 
Bisulfite Dilutent for each sample. The solution was then incubated at 60˚ C for 15 
minutes. This solution was added to 25 ul of the oxidized DNA solution and 5 ul of 
bisulfite additive and place in to a 0.2 ml PCR tube and centrifuged. These tubes were 
placed in a thermocycler. The thermocycler program followed the following program: 5 
minutes at 95˚ C followed by 20 minutes at 60˚ C, five minutes at 95˚ C followed by 40 
minutes at 60˚ C, 5 minutes at 95˚ C followed by 165 minutes at 60˚ C, 5 minutes at 95˚ 
C followed by 20 minutes at 60˚ C, 5 minutes at 95˚ C followed by 40 minutes at 60˚ C, 
and finally 5 minutes at 95˚ C followed by 20 minutes at 60˚ C. Then, the samples were 
centrifuged at 14000 x g to remove and salt contaminants. The supernatant was mixed 
with 310 ul of desulfonation buffer and transferred to an Amicon collection tube provided 
in the kit. The tube was centrifuged at 14,000 x g and the elute was discarded three times 
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and then washed three times with wash buffer. 
PCR Amplification 
The converted DNA was then amplified using TrueMethyl polymerase buffer, dNTPs, 
primers specific to the NGS adaptors and Truemethyl polymerase. The tube was then 
placed in a thermocycler and run at 95˚ C for 30 seconds, followed by 60˚ C for 20 
seconds followed by 72˚ C for 45 seconds fifteen times. 
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RESULTS 
Barak Scores of Tissue Donors 
 
 
Identification # 
Concentration 
(ng/ul) Volume (ul) Total DNA (ug) 
10640 8.07 1000 8.07 
10499 13.5 1000 13.5 
10427 15.5 1000 15.5 
21345 15.9 1000 15.9 
21400 18.3 1000 18.3 
21423 7.18 1000 7.18 
10544 8.05 1000 8.05 
21298 8.82 1000 8.82 
 
Table 2: Concentrations, volumes, and Total Obtained Genome from Samples. This data is obtained from samples before any 
efforts to concentrate them were executed. Oxidative bisulfite sequencing requires concentrations of at least 20 ng/ul and no 
above values match that requirement 
 
     
N=8 samples of frozen prefrontal ctx (1 each of Braak I-IV, 2 Braak V, and 2 Braak VI) 
PMI unspecified      
       
N PIN Diagnosis Braak Stage    
1 10640 Control 1    
2 10499 Control 2    
3 10427 AD 3    
4 21345 AD 4    
5 21400 AD 5    
6 21423 AD 5    
7 10544 AD 6    
8 21298 AD 6    
 
Table 1: Identification of Brain Sample Tissue. Eight human post-mortem brain samples were obtained from the Boston 
University School of Medicine Center for Alzheimer’s Disease with known diagnosis and Braak stage of the tissue. 
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Brain samples arrived to the lab stored on dry ice. No information was known about the 
donors besides their AD status based on the presence or absence of AD-like symptoms 
and diagnosed Braak stage at the time of death. Other factors that we would have wished 
to know and control including gender, age at death, racial background, and classical 
genetic predisposition to AD were not disclosed to us. 
Qubit Analysis 
 
Qubit analysis revealed initial difficulty of obtaining high yields of genomic DNA from 
the brain tissue. DNA concentrations were originally determined using NanoDrop 
technology. However, the recorded concentrations fell outside of the accurate reading 
range of NanoDrop technology. Original genomic DNA levels were very low (see table 
2) The reason for the low yields of genomic DNA was originally thought to be due to 
defects in the Qiagen DNA tissue extraction kit. However, once the extraction was 
Identification # 
Concentration 
(ng/ul) Volume (ul) Total DNA (ug) 
10640 31.3 100 3.13 
10499 32.3 100 3.23 
10427 29.4 100 2.94 
21345 35.2 100 3.52 
21400 44.8 100 4.48 
21423 23.8 100 2.38 
10544 26.8 100 2.68 
21298 56.6 100 5.66 
 
Table 3: Concentrations, volumes, and Total Obtained Genome after Concentration. 
This data was obtained from samples after efforts to concentrate them using 
ammonium acetate and isopropanol precipitation of DNA. Though the concentrations 
were greatly improved by the process, a significant amount of genome for each 
sample was lost in the process. 
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repeated using a phenol/chloroform extraction, no visible pellet of precipitated DNA was 
observed, leading to the possibility that the tissue contained low levels of genomic DNA. 
(See table 2) Several consecutive extractions yielded high volumes of low-concentration 
DNA. The samples were then concentrated to yield low volumes of highly concentrated 
DNA. (See table 3) The total amount of DNA available for the experiment was a large 
limitation. 
 
Dot Blot Analysis 
We report that dot blot analysis has shown that all eight samples of brain genome contain 
high levels of 5hmC and 5mC but undetectable levels in 5fC and 5caC. However, we 
report a present but mostly statistically insignificant drop in 5hmC as the progression of 
the disease ensues. This is consistent with previously reported data suggesting that 5hmC 
decreases during AD but otherwise increases with age. We report no major change, 
significant or otherwise, in 5mC levels during the progression of the disease.  Due to the 
scarcity of the genomic DNA for each Alzheimer’s sample, only one dot blot could be 
run for each sample for each primary antibody. 
5hmC 
The 5hmC dot blot revealed a visible trend of decreasing 5hmC levels with the 
progression of the disease. See figure 6 below. 
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The 5hmC blot was exposed for 25 seconds and scanned for analysis using the ImageJ 
program. Since the program measures the intensity of white contrasted against black, the 
image was converted to a negative and the average 5hmC expression per cell on the blot 
was measured using the white pixilation as a reference. High levels of expression 
corresponded with the lightest areas on the blot. Because the top row of the chart was 
overexposed, the next three rows were compiled together to generate the data. The 
expression levels were normalized by dividing each expression value by the largest value 
for each dilution. This way all dilutions were able to provide normalized data. The mean 
and the standard error were determined using the data sorted into four categories: healthy, 
Figure 6: Dot blot of 5hmC expression. All columns correspond to different samples. Samples are arranged from left to 
right in order of increasing progression of the disease. Theses samples were sorted into four categories with each 
category containing two samples. The first two correspond to healthy control. The second two (Braak III+BraakIV) are 
early stage Alzheimer’s. The next two (Braak V and Braak V) correspond to intermediate stage, and the final two (Braak VI 
and Braak VI) correspond to late stage Alzheimer’s. Rows on the blot correspond to levels of dilution of the DNA sample. 
Each descending row represents a 1:2 dilution. 
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early stage, intermediate stage, and late stage. All normalized data across each row was 
used. See figure 7 for results. Although the graph appears to demonstrate a small inverse 
correlation between 5hmC levels and the progression of the disease, a two-tailed t-test 
was run in order to determine any significant statistical difference between healthy levels 
and the values for the different categories. This t-test compared 5hmC levels between the 
healthy control and different points in the disease progression. The tests revealed no 
significant 
difference between healthy and early stage 5hmC (p=.211). There was a difference 
between 5hmC levels of healthy controls and those of late stage Alzheimer’s disease. 
There appears to be a decrease in 5hmC in the late stage. However, these differences 
were not statistically significant (p=.093) There was, however, a significant difference 
0 
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Figure 7: Normalized presence of 5hmC. Values of 5hmC were obtained from the ImageJ analysis of the corresponding dot blot. 
The program recognized the average brightness of each well as a function of total pixilation over the area of the well. Pixilation 
values were normalized by dividing all values for a particular sample by the largest value corresponding to that dilution with 1 
being the highest possible expression.  
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between healthy controls and the intermediate stage (p=.038). There is a statistical drop 
in 5hmC levels in the intermediate samples. 
5mC 
The same could not be reliably said about the 5mC data. Even at first glance at the 5mC 
dot blot, there seems to be little obvious trend. This was confirmed once the expression 
was measured by ImageJ. One problem associated with the blot is the relatively high 
background exposure which caused areas not marked by DNA to become slightly darker 
as well. (see figure 8). Once the data was entered, no statistical significance could be 
established. 
Figure 8: Dot blot of 5mC expression. All columns correspond to different samples. Samples are arranged from left to right in 
order of increasing progression of the disease. Theses samples were sorted into four categories with each category containing 
two samples. The first two correspond to healthy control. The second two (Braak III+BraakIV) are early stage Alzheimer’s. The 
next two (Braak V and Braak V) correspond to intermediate stage, and the final two (Braak VI and Braak VI) correspond to late 
stage Alzheimer’s. Rows on the blot correspond to levels of dilution of the DNA sample. Each descending row represents a 1:2 
dilution. 
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The p-values testing a significant difference between the healthy control group and the 
early stage, the healthy control group and the intermediate stage, and the healthy control 
group and the late stage were .450, .296, and .255 respectively. Since none of these 
numbers indicate significance, there is little that can be interpreted from this data. 
 
5fC and 5caC 
The dot blots for both of these DNA modifications appeared blank, even after exposing 
the film to the membrane for 15 minutes. We can infer that they were present at 
negligible levels in the genomes of these patients. Though we had predicted a negligible 
Figure 9: Normalized presence of 5mC. Values of 5mC were obtained from the ImageJ analysis of the corresponding dot blot. The 
program recognized the average brightness of each well as a function of total pixilation over the area of the well. Pixilation values 
were normalized by dividing all values for a particular sample by the largest value corresponding to that dilution with 1 being the 
highest possible expression.  
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presence across the board, we had predicted before that there would be a decrease in 5fC 
and 5caC during the progression of the disease since 5hmC was predicted to decrease as 
well and 5hmC is a precursor to 5fC and 5caC. However, this prediction was not 
supported by the data. 
Sequencing Results 
At the time of the deadline for this thesis, the sequencing results are still pending. If 
requested by the Boston University School of Medicine, an addendum to this thesis 
containing the sequencing data will be included and analyzed. 
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DISCUSSION 
At the point of writing and analyzing this thesis, the final results of the sequencing are 
currently pending. However, we were able to obtain a great deal of relevant evidence 
relating to the dynamics of DNA methylation and hydroxymethylation that will serve as 
the basis for future experiments, particularly in the Shi lab. The primary observation that 
can be drawn from this research is that there seems to be a correlation with the 
progression of the disease and a decrease in global genomic hydroxymethylation and a 
global increase in global genomic methylation due to comparisons of dot blots. Of 
course, it is hard to draw conclusions from the decrease in 5hmC. The only statistically 
significant drop in 5hmC presence occurs at the intermediate stage in disease progression. 
However, there actually seems to be a small increase in 5hmC levels as the disease 
progresses to the late stage. There are two possible explanations for this. One possibility 
is that the 5hmC levels as reported by intermediate data are artificially low. Indeed, there 
is an unmistakable artifact in one blot cell in the intermediate category that may be the 
result of non-uniform vacuuming of the dot blot apparatus. Another explanation is that 
there is a global increase in 5hmC in the final stage of Alzheimer’s disease resulting from 
some sort of compensatory action by the cell. 
There is little to be said about the 5mC data. No statistically significant difference could 
be established between any two points in the progression of the disease. We had 
predicted that 5mC levels would drop slightly. Perhaps this trend will be explained once 
the sequencing data has arrived. It is almost certainly the case that the role that DNA 
methylation plays in the progression of the disease is best explained as a shift in location 
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of methylation rather than as a global increase or decrease. 
The complete lack of visible expression of either 5fC or 5caC is not entirely surprising. 
Whereas 5hmC in the brain is a stable epigenetic mark, these two DNA modifications 
serve as intermediates that are quickly removed. They are present in very low numbers 
and for very small periods of time. 
There were several limitations that prevented us from establishing statistical significance 
in this study. The primary limitation was the relative difficulty of obtaining the number of 
brain samples required to establish a high power in the study. The successful negotiation 
of eight samples of human tissue for the sole purpose of promoting this master’s thesis 
remains one of the successes of the time devoted to this project. However, the division of 
these eight brain samples into four progression categories (healthy, early stage, 
intermediate stage, and late stage) meant that each category had only two brain samples 
from which to draw data. It is difficult to ascertain what if any conclusions about the 
population or about the disease in general based on such low sample numbers. With only 
two samples per category, it is no surprise that few trends in the data could reliably be 
called statistically significant. Should this study be repeated, it is important that more 
brain samples be procured. 
A second limitation of the study was the lack of controls on the brain samples. This study 
attempted to reveal the effect of disease progression on changes to the methylome and 
hydroxymethylome assuming all other factors were held constant. However, there was no 
way to adjust the results for age, race, gender, genetics, lifestyle, or environment of the 
sample patients. All such factors can alter the epigenome independently of disease 
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progression. All also may have a role to play in the progression of the disease. The effect 
that the probable differences in genotype alone had on the differences epigenetic 
modifications is worth a large and complicated study in of itself. Not only could we not 
account for such factors due to the low sample size and the lack of data that definitively 
establishes the epigenetic effects of each of factor, we were not even provided that 
information at the onset and we had no way of accounting for them. 
A third limitation was the relative low mass of each brain sample provided to us as well 
as the low amounts of obtainable genomic DNA contained in each sample. It remains to 
be shown if the low yields of genomic DNA is due to the techniques used to extract it or 
the tissue itself. Since most of the genomic DNA found in neurons in the brain is found in 
the cell bodies which are largely contained in the grey matter of the brain, it is possible 
that the location in the prefrontal cortex from which the sample was taken had an effect 
on our DNA yields. 
Despite some of the setbacks experienced during this project, we are happy to have 
generated the results that we have and eagerly anticipate the rest of the data when the 
sequencing results are finished. 
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FUTURE ENDEAVORS 
Since the main focus of this study as described in this thesis began as an attempt to fully 
sequence the hydroxymethylome and methylome of these specimens but shifted into 
establishing global trends, there is ample opportunity to finish the sequencing aspect of 
the project. This will ideally be finished in the next few months. 
Even when the sequencing data has returned, there is a severe limitation about what kinds 
of conclusions can be drawn from sequences of eight samples with two from each general 
stage in the progression. It lacks statistical power and there are several confounding 
factors including the age, gender, genetics, and even environment of each individual. 
What would have been more useful (if possible, practical, or ethical) would be to take 
brain samples from the same patients at various points in the progression of their disease 
in order to remove a variety of confounding epigenetic markers. Although it is impossible 
to perform such an experiment in vivo, the Shi lab currently is preparing to culture 
induced pluripotent neuronal stem cells derived from dermal tissue. These cells were 
obtained from individuals with known AD genotypes such as APOE4. The primary 
advantages of using these cells are that they are monoclonal and self-renewing. This 
solves two of the primary disadvantages of this study. The fact that they are monoclonal 
can help remove confounding factors associated with taking samples from different 
patients at different stages of the disease. These cells all are derived from one individual, 
allowing us to ignore the epigenetic differences resulting from the gender, age, race and 
genotype that likely confounded the results of this study. These cells can be sequenced at 
various points during the culturing process and this sequencing data can provide a clear 
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picture of how the methylome and hydroxymethylome change over time. Another 
excellent advantage of this strategy is that the cells can be chemically manipulated in 
ways that simulate oxidative stress, lipid, or amyloid build-up. There are several benefits 
to knowing the direct links between particular external stressors and changes in the 
epigenome. 
Of course, this study design presents an entire new array of problems— namely that the 
cells need to be cultured in a way that would simulate the environment stimuli to which 
AD neurons are exposed. Since the study of epigenetics looks for environmental effects 
on the genome and genome expression, the way that the cells were cultured would have 
some major confounding effects. If we could fully simulate the cerebral environment of a 
neuron, there would still be challenges to this model. We have established that cells 
besides the neurons themselves- namely microglia and astrocytes- are involved with AD 
pathogenesis and we would need to culture those as well. Despite the limitations of this 
future study, data generated from such as study could at least shed light on how particular 
genotypes associated with AD could impact the methylome and hydroxymethylome in 
affected neurons. 
Another possibility is that we could acquire transgenic mice with AD-associated alleles 
such as APOE4. These mice would be pre-programmed to undergo Alzheimer’s-like 
dementia after a few months. The primary advantage of this is that it maintains the 
monoculture that we would get with the induced neuronal stem cells. This could mean 
that if the mice are controlled for age and gender, all will have almost identical 
genotypes, lifestyles, and environmental exposures so that we can eliminate other 
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confounding effects on the epigenome. Also, different individuals from the monoculture 
could be sacrificed at different stages in the Alzheimer’s progression. The primary 
disadvantage of this is, like any animal study, the added cost, ethical considerations, and 
complexity of using live animals. 
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CONCLUSION 
We are happy to report that preliminary analysis of genomes obtained from Alzheimer’s 
patients revealed useful data. Data showed a statistically significant decrease in 5hmC 
levels in patients with intermediate stage Alzheimer’s disease compared to healthy 
individuals. This is consistent with previous literature describing decreasing 5hmC in the 
AD brain. It can be contrasted with other literature showing that 5hmC increases in a 
healthy brain. While more data is needed before this information is used as a diagnostic 
tool for aging patients experiencing possible Alzheimer’s-like symptoms, it does lay the 
groundwork for future discoveries that may provide medical science with a clearer model 
of the epigenetic and cellular pathways involved in the disease. This will be particularly 
evident once the exact sequences are completed. 
In addition to obtaining the data reported in this review, the skills learned during this 
experience have a great personal value. In addition to working with and collaborating 
with the many renowned researchers at the Endocrinology division at Brigham and 
Women’s Hospital, I was given the chance to help write multiple grants, develop and 
finalize an Harvard Medical School IACUC-approved animal protocol, order necessary 
reagents, and to participate in several ongoing experiments in the Shi lab. Beyond the 
techniques described in this thesis, I was also able to study and perform laboratory 
techniques including antibody pull-down of specific HA-flag transfected proteins relating 
to the epigenetic factors of breast cancer development, the culturing of human cells 
including human breast cancer cells and induced pluripotent stem cells, western blots, 
and care for laboratory animals including knockout mice. 
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